Legal & General Group Plc Buys 1,120 Shares of Prothena Corporation PLC (PRTA)
Legal & General Group Plc raised its stake in shares of Prothena Corporation PLC (NASDAQ:PRTA) by 8.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,708 shares of the biotechnology company’s stock after buying an additional 1,120 shares during the period. Legal & General Group Plc’s holdings in Prothena Corporation PLC were worth $740,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in the business. Bank of New York Mellon Corp lifted its position in shares of Prothena Corporation PLC by 7.8% in the second quarter. Bank of New York Mellon Corp now owns 185,462 shares of the biotechnology company’s stock worth $10,037,000 after buying an additional 13,492 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Prothena Corporation PLC by 16.2% during the 2nd quarter. SG Americas Securities LLC now owns 4,064 shares of the biotechnology company’s stock worth $220,000 after acquiring an additional 568 shares in the last quarter. State of Wisconsin Investment Board bought a new stake in shares of Prothena Corporation PLC during the 2nd quarter worth about $1,461,000. Denver Investment Advisors LLC increased its holdings in shares of Prothena Corporation PLC by 6.2% during the 2nd quarter. Denver Investment Advisors LLC now owns 7,470 shares of the biotechnology company’s stock valued at $404,000 after acquiring an additional 435 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Prothena Corporation PLC by 6.9% during the 2nd quarter. Rhumbline Advisers now owns 45,262 shares of the biotechnology company’s stock valued at $2,450,000 after acquiring an additional 2,936 shares during the last quarter.
Shares of Prothena Corporation PLC (PRTA) opened at 63.76 on Wednesday. Prothena Corporation PLC has a 52-week low of $40.58 and a 52-week high of $70.00. The stock has a 50 day moving average price of $61.21 and a 200 day moving average price of $57.11. The company’s market capitalization is $2.44 billion.
Prothena Corporation PLC (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.89) by $0.43. Prothena Corporation PLC had a negative return on equity of 33.20% and a negative net margin of 527.56%. The company had revenue of $26.81 million during the quarter, compared to analysts’ expectations of $16.08 million. During the same period last year, the firm posted ($1.18) earnings per share. The business’s revenue was up 7951.1% on a year-over-year basis. On average, analysts predict that Prothena Corporation PLC will post ($4.41) earnings per share for the current fiscal year.
In other news, insider Tara Nickerson sold 17,500 shares of the stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $63.60, for a total value of $1,113,000.00. Following the transaction, the insider now directly owns 19,500 shares of the company’s stock, valued at $1,240,200. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Karin L. Walker sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $64.89, for a total transaction of $324,450.00. Following the sale, the insider now owns 5,000 shares of the company’s stock, valued at approximately $324,450. The disclosure for this sale can be found here. In the last 90 days, insiders sold 34,424 shares of company stock worth $2,226,027. 3.10% of the stock is owned by company insiders.
A number of brokerages recently weighed in on PRTA. ValuEngine raised Prothena Corporation PLC from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $70.00 target price on shares of Prothena Corporation PLC in a report on Thursday, July 6th. Jefferies Group LLC started coverage on Prothena Corporation PLC in a research report on Monday, July 10th. They set a “buy” rating and a $100.00 target price for the company. BidaskClub raised Prothena Corporation PLC from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 19th. Finally, Zacks Investment Research upgraded Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $66.00 price target on the stock in a report on Friday, August 11th. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $78.58.
Prothena Corporation PLC Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Stock Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related stocks with our FREE daily email newsletter.